Skip to main content

Advertisement

SpringerLink
Log in

Pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in cynomolgus monkeys

  • Original Article
  • Published:
Naunyn-Schmiedeberg's Archives of Pharmacology Aims and scope Submit manuscript

Abstract

Mirabegron is a novel β3-adrenoceptor agonist developed for the treatment of overactive bladder. To clarify the relationship between the pharmacological effects of mirabegron in monkeys and the clinical efficacy in patients with overactive bladder, the effect of mirabegron on bladder function was evaluated using cynomolgus monkeys. Quantitative PCR revealed that mRNA expression of β3-adrenoceptors was most abundant (98 %) among β-adrenoceptor subtypes in the bladder of cynomolgus monkeys. Mirabegron, which showed selective and potent agonistic activity on monkey β3-adrenoceptors expressed in Chinese hamster ovary cells with EC50 value of 32 nmol/L and intrinsic activity of 0.8, induced concentration-dependent relaxation of bladder smooth muscle strips isolated from cynomolgus monkeys with EC50 values of 120 nmol/L in 20 mmol/L KCl stimulation and 43 nmol/L under 9.81 mN resting tension. In conscious cynomolgus monkeys, mirabegron decreased micturition frequency at oral doses of 1 and 3 mg/kg and increased mean volume voided per micturition at an oral dose of 3 mg/kg. Plasma concentration at which bladder function improved in the cynomolgus monkeys was similar to that at the clinically effective dose in patients with overactive bladder. These data suggest that the relaxant function in monkey bladder is mainly mediated by β3-adrenoceptors similar to that in the human bladder and mirabegron showed efficacy on the bladder functions of the same parameters in clinical evaluation endpoints.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  • Anderson GF, Marks BH (1984) Beta adrenoceptors in the rabbit bladder detrusor muscles. J Pharmacol Exp Ther 228:283–286

    PubMed  CAS  Google Scholar 

  • Andersson K-E (1999) Physiological Society symposium: the physiology and pathophysiology of the lower urinary tract. Advances in the pharmacological control of the bladder. Exp Physiol 84:195–213

    PubMed  CAS  Google Scholar 

  • Awad SA, Bruce AW, Carro-Ciampi G, Downie JW, Lin M, Marks GS (1974) Distribution of α- and β-adrenoceptors in human urinary bladder. Br J Pharmacol 50(4):525–529

    Article  PubMed  CAS  Google Scholar 

  • Hatanaka T, Ukai M, Watanabe M, Someya A, Ohtake A, Suzuki M, Ueshima K, Sato S, Sasamata M (2013a) In vitro and in vivo pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in rats. Naunyn Schmiedebergs Arch Pharmacol 386(3):247–253

    Article  PubMed  CAS  Google Scholar 

  • Hatanaka T, Ukai M, Watanabe M, Someya A, Ohtake A, Suzuki M, Ueshima K, Sato S, Kaku S (2013b) Effect of mirabegron, a novel β3-adrenoceptor agonist, on bladder function during storage phase in rats. Naunyn Schmiedebergs Arch Pharmacol 386(1):71–78

    Article  PubMed  CAS  Google Scholar 

  • Igawa Y, Yamazaki Y, Takeda H, Hayakawa K, Akahane M, Ajisawa Y, Yoneyama T, Nishizawa O, Andersson K-E (1999) Functional and molecular biological evidence for a possible β3-adrenoceptor in the human detrusor muscle. Br J Pharmacol 126:819–825

    Article  PubMed  CAS  Google Scholar 

  • Igawa Y, Schneider T, Yamazaki Y, Tatemichi S, Homma Y, Nishizawa O, Michel MC (2012) Functional investigation of β-adrenoceptors in human isolated detrusor focusing on the novel selective β3-adrenoceptor agonist KUC-7322. Naunyn Schmiedebergs Arch Pharmacol 385(8):759–767

    Article  PubMed  CAS  Google Scholar 

  • Khullar V, Amarenco G, Angulo JC, Cambronero J, Høye K, Milsom I, Radziszewski P, Rechberger T, Boerrigter P, Drogendijk T, Wooning M, Chapple C (2013) Efficacy and tolerability of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol 63(2):283–295

    Article  PubMed  CAS  Google Scholar 

  • Krauwinkel W, van Dijk J, Schaddelee M, Eltink C, Meijer J, Strabach G, van Marle S, Kerbusch V, van Gelderen M (2012) Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women. Clin Ther 34(10):2144–2160

    Article  PubMed  CAS  Google Scholar 

  • Li JH, Yasay GD, Kau ST (1992) β-Adrenoceptor subtypes in the detrusor of guinea-pig urinary bladder. Pharmacology 44:13–18

    Article  PubMed  CAS  Google Scholar 

  • Maruyama I, Tatemichi S, Goi Y, Maruyama K, Hoyano Y, Yamazaki Y, Kusama H (2012) Effects of ritobegron (KUC-7483), a novel selective β3-adrenoceptor agonist, on bladder function in cynomolgus monkey. J Pharmacol Exp Ther 342(1):163–168

    Article  PubMed  CAS  Google Scholar 

  • Nergårdh A, Boréus LO (1972) Autonomic receptor function in the lower urinary tract of man and cat. Scand J Urol Nephrol 6:32–36

    Article  PubMed  Google Scholar 

  • Nergårdh A, Boreus LO, Naglo A-S (1977) Characterization of the adrenergic β-receptor in the urinary bladder of man and cat. Acta Pharmacol Toxicol 40:14–21

    Article  Google Scholar 

  • Nomiya M, Yamaguchi O (2003) A quantitative analysis of mRNA expression of α1 and β-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol 170(2 Pt 1):649–653

    Article  PubMed  CAS  Google Scholar 

  • Otsuka A, Shinbo H, Hasebe K, Matsumoto R, Ozono S (2008) Effects of a novel β3-adrenoceptor agonist, AJ-9677, on relaxation of the detrusor muscle: an in vitro study. Int J Urol 15(12):1072–1076

    Article  PubMed  CAS  Google Scholar 

  • Seguchi H, Nishimura J, Zhou Y, Niiro N, Kumazawa J, Kanaide H (1989) Expression of β3-adrenoceptor in rat detrusor smooth muscle. J Urol 159:2197–2201

    Article  Google Scholar 

  • Takasu T, Ukai M, Sato S, Matsui T, Nagase I, Maruyama T, Sasamata M, Miyata K, Uchida H, Yamaguchi O (2007) Effect of (R)-2-(2-aminothiazol-4-yl)-4-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel Selective β3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 321:642–647

    Article  PubMed  CAS  Google Scholar 

  • Takeda M, Obara K, Mizusawa T, Tomita Y, Arai K, Tsutsui T, Hatanao A, Takahashi K, Nomura S (1999) Evidence for β3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J Pharmacol Exp Ther 288:1367–1373

    PubMed  CAS  Google Scholar 

  • Takeda H, Igawa Y, Komatsu Y, Yamazaki Y, Akahane M, Nishizawa O, Ajisawa Y (2000) Characterization of β-adrenoceptor subtypes in the ferret urinary bladder in vitro and in vivo. Eur J Pharmacol 403:147–155

    Article  PubMed  CAS  Google Scholar 

  • Takeda H, Yamazaki Y, Akahane M, Akahane S, Miyata H, Igawa Y, Nishizawa O (2002) Characterization of β-adrenoceptor subtype in bladder smooth muscle in cynomolgus monkey. Jpn J Pharmacol 88:108–113

    Article  PubMed  CAS  Google Scholar 

  • Yamaguchi O (2002) β3-adrenoceptors in human detrusor muscle. Urology 59(5 Suppl 1):25–29

    Article  PubMed  Google Scholar 

  • Yamazaki Y, Takeda H, Akahane M, Igawa Y, Nishizawa O, Ajisawa Y (1998) Species differences in the distribution of β-adrenoceptor subtypes in bladder smooth muscle. Br J Pharmacol 124:593–599

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors are grateful to Dr. Cees Korstanje (Astellas Pharma Europe B.V.) for helpful comments and suggestions.

Author information

Authors and Affiliations

  1. Pharmacology Research Laboratories, Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki, 305-8585, Japan

    Toshiki Hatanaka, Masashi Ukai, Mai Watanabe, Akiyoshi Someya, Akiyoshi Ohtake, Masanori Suzuki, Koji Ueshima, Shuichi Sato & Noriyuki Masuda

Authors
  1. Toshiki Hatanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masashi Ukai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mai Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Akiyoshi Someya
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Akiyoshi Ohtake
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masanori Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Koji Ueshima
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shuichi Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Noriyuki Masuda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Toshiki Hatanaka.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hatanaka, T., Ukai, M., Watanabe, M. et al. Pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in cynomolgus monkeys. Naunyn-Schmiedeberg's Arch Pharmacol 386, 1001–1008 (2013). https://doi.org/10.1007/s00210-013-0900-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00210-013-0900-1

Keywords

Search

Navigation